$PYYX

PYXUS INTERNATIONAL, INC. (PYYX): Submission of Matters to a Vote of Security Holders

PYXUS INTERNATIONAL, INC. (PYYX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders (a) On August 13, 2026 , Pyxus International, Inc. (the "Company") held its 2026 annual meeting of shareholders (the "Annual Meeting"). (b) At the Annual Meeting, the matters submitted to a vote of shareholders, and ou

Original reporting
Published Aug 13, 2026, 8:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 8:19 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$PYYX
Neutral
high confidence
Mentioned
$PYYX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PYYXNeutralLow
01

Why it matters

The disclosure confirms the director slate for a one-year term, ratifies Deloitte & Touche LLP as independent auditors for FY ending March 31, 2027, and records the advisory say-on-pay vote. These are standard corporate governance items and do not introduce new financial metrics or commitments.

02

Market read

Primarily a compliance/governance update; not a catalyst for fundamental repricing.

03

What to watch

Traders may instead focus on upcoming earnings, guidance, or any separate 8-K items; this filing alone is unlikely to change expectations.

Relevance 6/10Novelty 2/10Timing: after-hours filing of Aug. 13, 2026 8-K vote results

Background

The company submitted SEC Form 8-K under Item 5.07 to report matters voted on at its 2026 annual shareholder meeting.

Company-level read

Ticker impact

$PYYXNeutralHigh confidence
Context

Pyxus International filed an 8-K reporting the Aug. 13, 2026 annual meeting vote results, including director elections and auditor ratification.

Expected impact

Low likelihood of a sustained price move; any reaction should be muted and short-lived.

Evidence & confidence

The filing discloses standard governance items (director slate, Deloitte ratification, advisory say-on-pay) without new strategy, earnings, or material transactions.

Market effects

Minimal, as the disclosure is company-specific governance with no sector-wide signal.

None indicated.

None indicated.

Counterpoint

If there were unusual vote outcomes (not shown here), it could hint at governance dissatisfaction, but the provided results look routine.

Key entities

  • Pyxus International, Inc.

    Subject of the 8-K; reported annual meeting vote outcomes under Item 5.07.

  • Deloitte & Touche LLP

    Independent auditors ratified for the fiscal year ending March 31, 2027.

Related articles

$PYYXMed

Pyxus International Q1 Earnings Call Highlights

Pyxus International reported Q1 cost and cash-flow updates on its earnings call. Adjusted EBITDA fell to $27.7M from $29.5M, but rose on a rolling 12-month basis to $225M. Adjusted free cash flow improved to $123.4M (12-month). Cash was $175.9M with no ABL borrowings; leverage improved to 4.9x. Management discussed debt maturity resolution and expected stronger shipments.

$PYYXMedAI 9/10

Pyxus International, Inc. Reports First Quarter Fiscal 2027 Results

Pyxus International (OTCID: PYYX) reported first quarter fiscal 2027 results for the period ended June 30, 2026. Sales and other operating revenues fell to $437.8 million from $508.8 million. Operating income was $15.7 million vs. $21.0 million, and net loss was $7.3 million vs. $15.8 million. Adjusted EBITDA was $27.7 million. Pyxus maintained FY2027 guidance: net sales $2.3B to $2.5B and adjusted EBITDA $210M to $240M.

$PYYXMed

PYXUS INTERNATIONAL, INC. (PYYX): Results of Operations and Financial Condition

PYXUS INTERNATIONAL, INC. (PYYX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pyxus International, Inc. Tel: (919) 379-4300 6001 Hospitality Court Fax: (919) 379-4346 Suite 100 www.pyxus.com Morrisville, NC 27560-2009 USA NEWS RELEASE Contact: Tomas Grigera (919) 379-4300 Pyxus International, Inc. Reports First Quarter Fiscal 2027 Results Morr

$PYYXMedAI 9/10

Pyxus International, Inc. Reports Strong Fourth Quarter Performance, Concludes Year of Continued Positive Momentum

Pyxus International reported fiscal 2026 results ended March 31, 2026. Q4 net sales rose 35.2% to $678.2 million, and Q4 operating income increased to $43.7 million. For the full year, operating income rose to $162.7 million and net income to $14.6 million; adjusted EBITDA reached a record $226.7 million. Leverage improved to 3.52x. Company guidance for FY2027: sales $2.3–$2.5B and adjusted EBITDA $210–$240M.

$SNDKHigh

Sandisk Unveiled an $14 Billion Buyback and Warren Buffett Has Something to Say About It

Sandisk (NASDAQ: SNDK) announced a $14 billion stock buyback, following a $4.5 billion repurchase in Q4. The company's stock has surged 548% in 2026, driven by high demand for NAND flash memory. Sandisk's Q4 revenue reached $9 billion, up 372% year-over-year, with strong growth in its data center business. Warren Buffett supports buybacks when shares are bought below intrinsic value, citing Apple as an example.

$HALOMedAI 9/10

Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033

Halozyme Therapeutics (HALO) priced a $1.3B upsized offering of 1.50% convertible senior notes due 2033, with a 13-day option for additional $200M. Notes have an initial conversion price of $139.84, a 27.5% premium over the closing price. Proceeds (~$1.275B) will fund capped call transactions, repurchase existing notes, and general corporate purposes. The company expects to close the offering on September 22, 2026.